TG Therapeutics Announces Publication of Final Results from the Phase 3 GENUINE Trial Evaluating Ublituximab Plus Ibrutinib in Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia in The Lancet Haematology

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement